CD79A and cancer: Previously it has been shown that non‐antigen specific dimeric IgA could enhance T cell‐mediated killing of PIGR‐expressing cancer cells in an MHC‐I independent manner, therefore, there is a high chance that therapeutic use of dimeric IgA antibodies could also promote cytotoxic killing by CD8 T cells, in addition to ADCC/ADCP.